-
The tens of billions of diabetes drug market has become a new focus of local drug companies
Time of Update: 2021-10-21
Recently, Huadong Medicine announced that it signed an exclusive product commercialization agreement with multinational pharmaceutical company Takeda (Takeda Pharmaceutical), and obtained the exclusive commercialization of Takeda Pharmaceutical’s innovative product Alogliptin benzoate tablets (trade name: Nisina) in mainland China Equity .
-
The AI pharmaceutical track is hot, and another leading pharmaceutical company successfully IPO
Time of Update: 2021-10-21
Early shareholders such as Sequoia Capital and Wuyuan Capital continued to make additional investments; in early August, Shenzhen Technology announced that it had completed a series of tens of millions of dollars in A round of financing led by Hillhouse Ventures and co-invested by Matrix Partners China and Baitu Shengke .
-
Domestically-made innovative drugs are going overseas, and new progress is being made
Time of Update: 2021-10-21
On October 8, China Biopharmaceuticals issued a corporate announcement stating that the company’s self-developed innovative drug "TCR1672" has been submitted to the U.
Andorra's new anti-cancer drug AND019 has been approved for clinical use in the United States Hangzhou Andorra's third-generation oral breast cancer class 1 new drug AND019, independently developed by Hangzhou Andorra Co.
-
Digitization empowers the Chinese medicine industry and accelerates its entry into the "fast lane of development"
Time of Update: 2021-10-21
In recent years, with the increasing demand for health and the emergence and development of new technologies such as the Internet, big data, and artificial intelligence, China's traditional Chinese medicine market has also begun to be injected with new vitality .
-
FDA blockbuster drug approval plan in October 2021
Time of Update: 2021-10-21
CompilenewbornAs of September this year, the US FDA has approved a total of 40 innovative drugs, compared with 40 in the same period last year and 53 in the whole year of last year .
Entering October, a number of drugs will usher in an important review decision by the FDA .
-
ALK-1 monoclonal antibody/Opdivo combination for first-line treatment of advanced liver cancer is clinically approved in China
Time of Update: 2021-10-21
Pioneer Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has recently approved its ALK-1 monoclonal antibody (GT90001C), and Bristol-Myers Squibb's (BMS) anti-PD-1 monoclonal antibody nivolumab (English trade name Opdivo) Combined clinical trial for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have not been systemically treated .
-
Within one month, nearly 500 institutions intensively investigated this medical device company
Time of Update: 2021-10-21
According to Wind data, in the first three quarters of 2021, 2,506 A-share companies have disclosed their investor relations activity records, a significant increase of more than 1,000 over the same period of the previous year .
-
The Pharmacopoeia Commission publicizes draft national standards for 14 varieties of chemical drugs
Time of Update: 2021-10-21
cnMailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, BeijingPost Code: 100061National Pharmacopoeia CommitteeOctober 09, 2021Attachment: Salbutamol Sulfate Orally Disintegrating Tablets-Publication Draft.
-
The impact of new crown oral drugs against the epidemic and vaccines
Time of Update: 2021-10-21
On October 1, Merck announced the interim analysis data of its new crown oral specific drug molnupiravir (monupivir) in the mild phase III MOVe-OUT study.
-
Under the license in fever, pharmaceutical companies must avoid "false innovations"
Time of Update: 2021-10-21
At present, for companies, the industry believes that they still need to continuously improve the level of innovation and focus on the clinical value of drugs in order to move towards a good future .
-
China Medical City has entered the stage of industrialization, and three more pharmaceutical companies have been approved for drug production licenses
Time of Update: 2021-10-21
The author has learned that recently, three more companies in China Medical City have successively obtained drug production licenses issued by the Jiangsu Provincial Drug Administration, and have officially entered the stage of industrialization .
-
September Pharmaceutical Events: Corporate Issues: Frequent Major Actions such as Investment and Acquisitions of Listed Companies
Time of Update: 2021-10-21
Jilin Aodong announced on the evening of September 13 that the company has recently received the "Notice of Share Increase Plan" from the controlling shareholder Jincheng Company .
-
FDA grants AstraZeneca Tezepelumab orphan drug certification for the treatment of EoE
Time of Update: 2021-10-21
In addition, in the subgroup of patients with a baseline eosinophil count of <300 cells/μl, the trial also reached the primary endpoint: compared with placebo+SoC, tezepelumab+SoC treatment made AAER statistically significant and Decrease of clinical significance .
-
Leading domestic pharmaceutical equipment industry, performance is expected to usher in a period of continuous growth
Time of Update: 2021-10-21
. The industry predicts that in the context of the favorable pharmaceutical environment, the continuous optimization of the pharmaceutical competition pattern and the continuous increase of market concentration, the profitability of pharmaceutical equipment companies will gradually increase in the future .
-
"Seeing the leopard in a tube", how is the boom in the three quarterly reports of the pharmaceutical equipment industry?
Time of Update: 2021-10-21
In addition to Tofflon, many pharmaceutical equipment companies have also announced the three quarterly report appointment disclosure dates.
Many domestic pharmaceutical companies have accelerated their internationalization strategy this year, and overseas business is expected to usher in a new round of growth .
-
Directors, deputy general managers...The wave of resignations of senior executives of listed pharmaceutical companies continues!
Time of Update: 2021-10-21
Kangyuan Pharmaceutical: Director resigns On October 11, Kangyuan Pharmaceutical announced that the company’s board of directors recently received a resignation report from Director, Deputy General Manager, Board Secretary and Chief Financial Officer Yin Honggang.
-
Shanxi Province Chinese Medicine Formula Granule Management Implementation Rules (Draft for Solicitation of Comments) Released
Time of Update: 2021-10-21
Manufacturers that carry out production filing or sales filing shall submit relevant filing materials through the "Chinese Medicine Formula Granule Recording Management Module of the Pharmaceutical Business Application System of the State Drug Administration" (hereinafter referred to as the formula granule filing module) in accordance with the procedures and requirements .
-
Corium Donepezil transdermal patch Adlarity new drug application is expected to be approved next year
Time of Update: 2021-10-21
On October 12, 2021, Corium announced that the US FDA has set the new drug application (NDA) PDUFA target date for its donepezil (donepezil) transdermal patch Adlarity to March 11, 2022 for the treatment of mild/medium/ Patients with dementia caused by severe Alzheimer's disease .
-
Mengke Pharmaceutical is selected as the 2020 Shanghai High-tech Enterprise Cultivation List
Time of Update: 2021-10-21
"Being selected into the 2020 Shanghai High-tech Enterprise Storage Cultivation List marks that Mengke Pharmaceutical's scientific research and innovation capabilities have once again been recognized by the authority .
-
Chain giants have a new acquisition!
Time of Update: 2021-10-20
According to relevant data, the number of Yifeng stores in Central and South China has increased from 559 in 2015 to 2,858 by the end of 2020, an increase of more than 2,000 in five years .
